Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manuel de Jesus Diaz Verduzco has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America

    by Ricardo G. Figueiredo, Nathalia Filgueiras Vilaça Duarte, Daniela Carla Barbosa Campos, Manuel de Jesus Diaz Verduzco, Ángel Alemán Márquez, Gabriela Tannus Branco de Araujo, Adalberto Sperb Rubin

    Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists. The patient’s journey in both countries begins when the patient seeks medical care after observing a chronic respiratory symptom. In both countries, due to diagnostic complexity, these patients arrive at ILD referral centers at an advanced stage of the disease. Once diagnosis is established, the treatment onset differs between Mexico and Brazil. In Brazil, access to antifibrotic drugs through the public health system has been a significant challenge, and their cost makes them unaffordable for most people. This situation forces medical specialists to provide only supportive care to patients until these drugs can be accessed. In Mexico, antifibrotics have been available in health sectors since 2018. Brazil and Mexico have several similarities regarding the initial journey of the patient due to diagnosis difficulties. Still, the outcome tends to be different due to a difference in access to treatment with antifibrotics. For this reason, advancing health policies that ensure proper treatment for patients with ILD is crucial for the sustainability and reliability of the health system.


  • Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical Characteristics, Evolution and Treatment

    by Fabián Caro, Ivette Buendía-Roldán, Lorena Noriega-Aguirre, María L. Alberti, Alexandre Amaral, Guillermo Arbo, Santiago Auteri, Aníbal Bermúdez, Pablo Curbelo, Manuel de Jesús Díaz Verduzco, et al.


    • 25 February 2006
      • Vol. 44  (1) , 35-8

    [Community-acquired pneumonia: risk focus and family functionality].

    by David López Del Castillo-Sánchez, Enrique Sabag-Ruiz, Manuel De Jesús Díaz-Verduzco, Mario Alonso Monzón-Vega

    Community-acquired pneumonia is one of the five most prevalent causes of death worldwide; in Mexico, it accounts for more than 10% of the hospital admissions. To identify the risk factors and the kind of family functionality associated to community-acquired pneumonia among adult patients. With the prior authorization of the research and bioethics committees, a study of cases and controls took place, where both groups were asked about the following variables: alcohol consumption or active smoking, conditions of house and family functionality, anti-flu and anti-pneumococcal vaccination, disablement, and chronic pulmonary disease, among others. It was found that the significant variables were active smoking, disablement, pulmonary emphysema, chronic bronchitis, overcrowding at home, and alcohol consumption; and with a protective effect for this disease: a functional family and anti-pneumococcal vaccination. There are risk factors that predispose the development of community-acquired pneumonia, and that allow us to make a population profile in which some preventive strategy could diminish the frequency and lethality of this disease.